Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Identification and characterisation of a salt form of Danirixin with reduced pharmacokinetic variability in patient populations.

Bloomer JC, Ambery C, Miller BE, Connolly P, Garden H, Henley N, Hodnett N, Keel S, Kreindler JL, Lloyd RS, Matthews W, Yonchuk J, Lazaar AL.

Eur J Pharm Biopharm. 2017 Aug;117:224-231. doi: 10.1016/j.ejpb.2017.03.023. Epub 2017 Apr 3.

PMID:
28385615
2.

The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist --in healthy adult subjects.

Miller BE, Mistry S, Smart K, Connolly P, Carpenter DC, Cooray H, Bloomer JC, Tal-Singer R, Lazaar AL.

BMC Pharmacol Toxicol. 2015 Jun 20;16:18. doi: 10.1186/s40360-015-0017-x.

3.

The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers.

Miller BE, Smart K, Mistry S, Ambery CL, Bloomer JC, Connolly P, Sanderson D, Shreeves T, Smith R, Lazaar AL.

Eur J Drug Metab Pharmacokinet. 2014 Sep;39(3):173-81. doi: 10.1007/s13318-014-0179-8. Epub 2014 Feb 7.

4.

Impact of physiologically based pharmacokinetic modeling and simulation in drug development.

Shardlow CE, Generaux GT, Patel AH, Tai G, Tran T, Bloomer JC.

Drug Metab Dispos. 2013 Dec;41(12):1994-2003. doi: 10.1124/dmd.113.052803. Epub 2013 Sep 5.

PMID:
24009310
5.

Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.

Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.

Chem Res Toxicol. 2012 Oct 15;25(10):2067-82. doi: 10.1021/tx300075j. Epub 2012 Sep 19.

PMID:
22931300
6.

Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling.

Bloomer JC, Nash M, Webb A, Miller BE, Lazaar AL, Beaumont C, Guiney WJ.

Br J Clin Pharmacol. 2013 Feb;75(2):488-96. doi: 10.1111/j.1365-2125.2012.04352.x.

7.

Utilizing drug-drug interaction prediction tools during drug development: enhanced decision making based on clinical risk.

Shardlow CE, Generaux GT, MacLauchlin CC, Pons N, Skordos KW, Bloomer JC.

Drug Metab Dispos. 2011 Nov;39(11):2076-84. doi: 10.1124/dmd.111.039214. Epub 2011 Aug 10.

PMID:
21832001
8.

Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT "pie".

Riches Z, Stanley EL, Bloomer JC, Coughtrie MW.

Drug Metab Dispos. 2009 Nov;37(11):2255-61. doi: 10.1124/dmd.109.028399. Epub 2009 Aug 13.

9.
10.

A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation.

Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, Rostami-Hodjegan A.

Curr Drug Metab. 2006 Apr;7(3):315-34. Review.

PMID:
16611025
11.

The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.

Blackie JA, Bloomer JC, Brown MJ, Cheng HY, Hammond B, Hickey DM, Ife RJ, Leach CA, Lewis VA, Macphee CH, Milliner KJ, Moores KE, Pinto IL, Smith SA, Stansfield IG, Stanway SJ, Taylor MA, Theobald CJ.

Bioorg Med Chem Lett. 2003 Mar 24;13(6):1067-70.

PMID:
12643913
12.

The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.

Blackie JA, Bloomer JC, Brown MJ, Cheng HY, Elliott RL, Hammond B, Hickey DM, Ife RJ, Leach CA, Lewis VA, Macphee CH, Milliner KJ, Moores KE, Pinto IL, Smith SA, Stansfield IG, Stanway SJ, Taylor MA, Theobald CJ, Whittaker CM.

Bioorg Med Chem Lett. 2002 Sep 16;12(18):2603-6.

PMID:
12182870
13.

1-(Arylpiperazinylamidoalkyl)-pyrimidones: orally active inhibitors of lipoprotein-associated phospholipase A(2).

Bloomer JC, Boyd HF, Hickey DM, Ife RJ, Leach CA, Macphee CH, Milliner KJ, Pinto IL, Rawlings DA, Smith SA, Stansfield IG, Stanway SJ, Taylor MA, Theobald CJ, Whittaker CM.

Bioorg Med Chem Lett. 2001 Jul 23;11(14):1925-9.

PMID:
11459662
14.

CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.

Kenworthy KE, Bloomer JC, Clarke SE, Houston JB.

Br J Clin Pharmacol. 1999 Nov;48(5):716-27.

15.

In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole.

Bloomer JC, Clarke SE, Chenery RJ.

Drug Metab Dispos. 1997 Jul;25(7):840-4.

PMID:
9224778
16.

Determination of P4501A2 activity in human liver microsomes using [3-14C-methyl]caffeine.

Bloomer JC, Clarke SE, Chenery RJ.

Xenobiotica. 1995 Sep;25(9):917-27.

PMID:
8553685
17.

Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9.

Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ.

Xenobiotica. 1995 Mar;25(3):261-70.

PMID:
7618352
18.

Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron.

Bloomer JC, Baldwin SJ, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ.

Br J Clin Pharmacol. 1994 Dec;38(6):557-66.

19.

Metabolism and disposition of 14C-granisetron in rat, dog and man after intravenous and oral dosing.

Clarke SE, Austin NE, Bloomer JC, Haddock RE, Higham FC, Hollis FJ, Nash M, Shardlow PC, Tasker TC, Woods FR, et al.

Xenobiotica. 1994 Nov;24(11):1119-31.

PMID:
7701853
20.

Lauric acid as a model substrate for the simultaneous determination of cytochrome P450 2E1 and 4A in hepatic microsomes.

Clarke SE, Baldwin SJ, Bloomer JC, Ayrton AD, Sozio RS, Chenery RJ.

Chem Res Toxicol. 1994 Nov-Dec;7(6):836-42.

PMID:
7696540
21.

The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes.

Bloomer JC, Woods FR, Haddock RE, Lennard MS, Tucker GT.

Br J Clin Pharmacol. 1992 May;33(5):521-3.

22.

Effects of routes of administration of TCNU on its plasma, tissue and tumour concentrations.

Double JA, Bibby MC, Loadman PM, Bloomer JC.

Eur J Cancer Clin Oncol. 1988 Aug;24(8):1355-60.

PMID:
3181256

Supplemental Content

Loading ...
Support Center